CD33 and CD123 are the most used targets, but recently CAR-NK cells directed against NKG2D, CD70, CD38, and CLL1 have been generated and proved cytotoxic activity in AML preclinical studies [138,139,140,141]. The gene discussed is IL3RA; the disease is acute myeloid leukemia.